Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma

Eur Urol Oncol. 2022 Dec;5(6):719-721. doi: 10.1016/j.euo.2022.01.004. Epub 2022 Jan 31.

Authors

Chris Labaki¹, Ziad Bakouny¹, Guru Sonpavde¹, Toni K Choueiri¹, Eliezer M Van Allen²

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
² Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: eliezerm_vanallen@dfci.harvard.edu.

PMID: 35105532
DOI: 10.1016/j.euo.2022.01.004

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Carcinoma, Transitional Cell* / drug therapy
Carcinoma, Transitional Cell* / pathology
Humans
Immunoconjugates* / therapeutic use
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / pathology

Substances

Immunoconjugates
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized